XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
XPO1表达会加重预后不良的弥漫性大B细胞淋巴瘤(DLBCL)的病情,而当不存在突变型p53时,塞利尼索(selinexor)可有效靶向治疗DLBCL。
期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-020-00982-3
Deng, Manman; Zhang, Mingzhi; Xu-Monette, Zijun Y; Pham, Lan V; Tzankov, Alexandar; Visco, Carlo; Fang, Xiaosheng; Bhagat, Govind; Zhu, Feng; Dybkaer, Karen; Chiu, April; Tam, Wayne; Zu, Youli; Hsi, Eric D; Choi, William W L; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andrés J M; Møller, Michael B; Parsons, Benjamin M; van Krieken, J Han; Piris, Miguel A; Winter, Jane N; Hagemeister, Fredrick; Alinari, Lapo; Li, Yong; Andreeff, Michael; Xu, Bing; Young, Ken H